Telich-Tarriba JE, Pérez-Ortíz AC, Telich-Vidal J

Language: Spanish
References: 24
Page: 462-465
PDF size: 132.04 Kb.

ABSTRACT

Background: mucormycosis are opportunistic infections with high morbidity and mortality caused by fungi of the class Zygomycetes, they mainly affect diabetic and immunocompromised patients. In up to 20% of all cases the main infection is localized in the skin, with a great number of them presenting in healthy patients that have suffered from severe trauma or burns. Zygomycetes tend to invade arteries, which leads to thrombosis and generates wide necrotic areas; this favors the progress of the infection and invasion of deep tissues. Up to 24% of primary cutaneous mucormycosis can be complicated with necrotizing fasciitis.
Clinical case: we present the case of a 52 year-old male that received the clinical diagnosis of necrotizing fasciitis. The patient received wide spectrum antibiotics and was submitted to extensive debridment of the wound bed; transoperative biopsy revealed the presence of zygomicetes in the tissues and the diagnosis of primary cutaneous zygomicosis was made. Antifungal treatment with amphotericin B was initiated and two weeks later autologous skin grafts were applied over the wounds.
Conclusion: a high index of suspicion is needed to diagnose cutaneous zygomicosis, therefore it should always be considered amongst the differentials of necrotic wounds that do not respond to standard treatment. The rapid evolution of the disease remarks the importance of biopsying the wound bed early and treating aggresively.

REFERENCES

1. Patiño JF, Castro D. Necrotizing lesions of soft tissues: a review. World J Surg 1991;15(2):235-239.

2. Jain D, Kumar Y, Vasishta RK, Rajesh L, Pattari SK, Chakrabarti A. Zigomycotic necrotizing fasciitis in inmunocompetent patients: a series of 18 cases. Mod Pathol 2006;19(9):1221-1226.

3. Wall S, Lee KH, Alvarez JD, Bigelow DC. Quiz case, 1. Cutaneous mucormycosis of the external ear. Arch Otolaryngol Head Neck Surg 2000;126:236-239.

4. Elgart ML. Zygomycosis. Dermatologic Clinic 1996;14:141-146.

5. Carvalhal GF, Machado MG, Pompeo A, Saldaña L, Sabbaga E, Arap S. Mucormycosis presenting as a renal mass in a patient with the human immunodeficiency virus. J Urol 1997;158:2230-2231.

6. Torres Narbona M, Guinea J, Muñoz P, Bouza E. Zigomicetos y zigomicosis en la era de las nuevas terapias antifúngicas. Rev Esp Quimioterap 2007;20:375-386.

7. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41(5):634-653.

8. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: Update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006;20(3):581-607.

9. Solano T, Atkins B, Tambosis E, Mann S, Gottlieb T. Disseminated mucormycosis due to Saksenaea vasiformis in an immunocompetent adult. Clin Infect Dis 2000;30:942-943.

10. Pérez-Uribe A, Molina de Soschin D, Arenas R, Reyes M. Mucormicosis cutánea primaria en un paciente con virus de la inmunodeficiencia humana. Revista Iberoam Micol 2005;22:118-121.

11. Chen CK, Wan SH, Kou SK. A rare cutaneous fungal infection complicating bacterial necrotising fasciitis. Hong Kong Med J 2008;14(4):314-316.

12. Chander J, Kaur J, Attri A, Mohan H. Primary cutaneous zygomycosis from a tertiary care centre in north-west India. Indian J Med Res 2010;131:765-770.

13. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011;17(12):1859-1867.

14. Mathews MS, Raman A, Nair A. Nosocomial zygomycosis post-surgical necrotizing fasciitis in a healthy adultcaused bu Apophysomyces elegans in South India. J Med Vet Mycol 1997;35:61-63.

15. Nouri-Majalan N, Moghimi M. Skin mucormycosis presenting as an erythema-nodosum-like rash in a renal transplant recipient: a case report. J Med Case Reports 2008;2:112.

16. Severo CB, Guazzelli LS, Severo LC. Chapter 7: zygomycosis. J Bras Pneumol 2010;36(1):134-141.

17. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009;48(12):1743-1751.

18. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: A review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004;10(Suppl 1):31-47.

19. Armáiz-García ME, Alonso-Peña D, González-Vela MC, García- Palomo JD, Sanz-Giménez-Rico JR, Arnáiz-García AM. Cutaneous mucormycosis: report of five cases and review of the literatura. J Plast Reconstr Aesthet Surg 2009;62(11):e434-e441.

20. Sánchez REC, Telich VJ, García CL, Crespo SA. Aplicaciones de la terapia con oxigenación hiperbárica en cirugía plástica. Cir Plast 2001;11(1):25-32.

21. Tragiannidis A, Groll AH. Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis. Clin Microbiol Infect 2009;15(Suppl 5):82-86.

22. Bentur Y, Shupak A, Ramon Y, Abramovich A, Wolfin G, Stein H, et al. Hyperbaric oxygen therapy for cutaneous/soft-tissue zygomycosis complicating diabetes mellitus. Plast Reconstr Surg 1988;102(3):822-824.

23. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 2004;23:769-773.

24. Rodríguez MM, Calvo E, Mariné M, Pastor FJ, Fernandez-Ballart J, Guarro J. Efficacy of Liposomal Amphotericin B Combined with Gamma Interferon or Granulocyte-Macrophage Colony-Stimulating Factor for Treatment of Systemic Zygomycosis in Mice. Antimicrob Agents Chemother. 2009;53(8):3569-3571.